Alvimopan
A peripherally acting mu-opioid receptor antagonist that blocks opioid effects specifically in the gut without crossing into the brain, used to accelerate the recovery of bowel function after bowel surgery. By restoring normal gut motility in patients who receive opioid pain medications after operations, it helps reduce the duration of post-surgical paralytic ileus.
Molecular Weight
424.5000 g/mol
LogP
1.70
TPSA
89.90 Ų
Lipinski RO5
Pass
Therapeutic Areas
Mechanism of Action
Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …
2D Structure
Cite this structure
Embed this structure
SMILES
C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(=O)O)CC[C@@]1(C)c1cccc(O)c1
InChI
InChI=1S/C25H32N2O4/c1-18-16-27(12-11-25(18,2)21-9-6-10-22(28)14-21)17-20(24(31)26-15-23(29)30)13-19-7-4-3-5-8-19/h3-10,14,18,20,28H,11-13,15-17H2,1-2H3,(H,26,31)(H,29,30)/t18-,20-,25+/m0/s1
Molecular Formula
C25H32N2O4
HBD / HBA
3 / 5
Rotatable Bonds
8
Heavy Atoms
31
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
A peripherally acting mu-opioid receptor antagonist that blocks opioid effects specifically in the gut without crossing into the brain, used to accelerate the recovery of bowel function after bowel surgery. By restoring normal gut motility in patients who receive opioid pain medications after operations, it helps reduce the duration of post-surgical paralytic ileus.
Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.
Yes, Alvimopan is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL270190. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5488548. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="alvimopan"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/alvimopan/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/alvimopan/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/alvimopan/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="alvimopan"></drugfyi-drug>